Tuberous Sclerosis Complex (TSC)
Rare Disease·MeSH: Tuberous Sclerosis
Prevalence
5.0 / 100K
2 drugs in development·2 companies·2 clinical trials
Drug Pipeline by Phase
Approved(1)
| Drug | Company |
|---|---|
| afinitor | Novartis AG (NVS) |
Phase 3(1)
| Drug | Company |
|---|---|
| ANAVEX®2-73 | ANAVEX LIFE SCIENCES CORP. (AVXL) |
Compare drugs
Frequently asked questions
How many drugs are in development for Tuberous Sclerosis Complex (TSC)?
BioSniper tracks 2 drugs in development for Tuberous Sclerosis Complex (TSC) across 2 companies.
How many clinical trials target Tuberous Sclerosis Complex (TSC)?
There are 2 clinical trials targeting Tuberous Sclerosis Complex (TSC) tracked by BioSniper.
What is the prevalence of Tuberous Sclerosis Complex (TSC)?
The estimated prevalence of Tuberous Sclerosis Complex (TSC) is approximately 5.0 per 100,000 population.
Deep-dive into Tuberous Sclerosis Complex (TSC)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis